BORMANN-KENNEDY BARBARA-JEAN ANNE
SEC insider (Form 3/4/5 filer). CIK 0001635065. Director at Xeris Biopharma Holdings, Inc. (XERS) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jun 4, 2026. Located in CHICAGO, IL.
Companies BORMANN-KENNEDY BARBARA-JEAN ANNE has filed insider reports for
- Xeris Biopharma Holdings, Inc. (XERS): Director
- BioLineRx Ltd. (BLRX): Director
BORMANN-KENNEDY BARBARA-JEAN ANNE
CIK: 0001635065
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (50.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 4, 2026XERS
Xeris Biopharma Holdings, Inc.
SaleDirect16K shares at avg. $6.09$98K - Jun 4, 2026XERS
Xeris Biopharma Holdings, Inc.
AwardDirect24.2K shares- - Dec 12, 2025XERS
Xeris Biopharma Holdings, Inc.
SaleDirect15K shares at avg. $7.09$106K - Jun 4, 2025XERS
Xeris Biopharma Holdings, Inc.
AwardDirect50K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 4, 2026 |  XERS Xeris Biopharma Holdings, Inc. | Sale | 16,000 | $6.09 | $97,507 | Direct |
| Jun 4, 2026 | XERS Xeris Biopharma Holdings, Inc. | Award | 24,193 | - | $0 | Direct |
| Dec 12, 2025 | XERS Xeris Biopharma Holdings, Inc. | Sale | 15,000 | $7.09 | $106,415 | Direct |
| Jun 4, 2025 | XERS Xeris Biopharma Holdings, Inc. | Award | 50,000 | - | - | Direct |
1-4 of 4 transactions